-
公开(公告)号：US20180353622A1
公开(公告)日：2018-12-13
申请号：US16003683
申请日：2018-06-08
Inventor： Lawrence LUM , Rubina TULADHAR , Tae Hyun HWANG , Yunku YEU , John Tyler PIAZZA , Quinn BARRETT
CPC classification number: A61K48/0066 , A61K38/465 , C12N15/11 , C12N2310/20
Abstract: Disclosed herein are methods for gene inactivation or rescue by cutting genomic DNA at regions of putative exon splicing enhancers with CRISPR-type enzymes.
-
Patent Agency Ranking
公开(公告)号：US20140038922A1
公开(公告)日：2014-02-06
申请号：US13875170
申请日：2013-05-01
Inventor： Lawrence LUM , Michael G. ROTH , Baozhi CHEN , Chuo CHEN , Michael E. DODGE , Wei TANG
IPC: C07D209/48 , C07D401/10 , C07D471/04 , C07D401/12 , C07D401/14
CPC classification number: A61K31/519 , A61K31/502 , A61K45/06 , C07D209/48 , C07D209/94 , C07D239/54 , C07D401/10 , C07D401/12 , C07D401/14 , C07D403/10 , C07D413/04 , C07D417/12 , C07D471/04 , C07D519/00
Abstract: The present invention generally relates to protein signalling. In particular, compounds that inhibit the Wnt protein signalling pathway are disclosed. Such compounds may be used in the treatment of Wnt protein signalling-related diseases and conditions such as cancer, degenerative diseases, type II diabetes and osteopetrosis.
Abstract translation: 本发明一般涉及蛋白信号传导。 特别地，公开了抑制Wnt蛋白信号通路的化合物。 这些化合物可用于治疗Wnt蛋白信号传导相关疾病和病症如癌症，退行性疾病，II型糖尿病和骨细胞减少症。
-
公开(公告)号：US20160115177A1
公开(公告)日：2016-04-28
申请号：US14890905
申请日：2014-05-14
Inventor： Lawrence LUM , Chuo CHEN
IPC: C07D495/04 , A61K45/06 , A61N5/10 , A61K31/519
CPC classification number: C07D495/04 , A61K31/519 , A61K45/06 , A61N5/10 , A61K2300/00
Abstract: The present invention generally relates to protein signalling. In particular, compounds that inhibit the Wnt protein signalling pathway are disclosed. Such compounds may be used in the treatment of Wnt protein signalling-related diseases and conditions such as cancer, degenerative diseases, type II diabetes and osteopetrosis.
Abstract translation: 本发明一般涉及蛋白信号传导。 特别地，公开了抑制Wnt蛋白信号通路的化合物。 这些化合物可用于治疗Wnt蛋白信号传导相关疾病和病症如癌症，退行性疾病，II型糖尿病和骨细胞减少症。
-
公开(公告)号：US20190202804A1
公开(公告)日：2019-07-04
申请号：US16330050
申请日：2017-08-31
Inventor： Nageswari YARRAVARAPU , Chuo CHEN , Lawrence LUM , Lin YOU , Chengwei ZHANG , Xiaolei WANG , Lishu ZHANG
IPC: C07D401/12 , C07D401/14 , C07D255/02
CPC classification number: C07D401/12 , A61K31/4192 , A61K31/4439 , A61K31/444 , A61K31/506 , A61K45/06 , C07D255/02 , C07D401/14 , C07D405/14 , C07D409/14
Abstract: The present disclosure provides compounds that may be useful for inhibiting Wnt pathway comprising compounds of the formula: (Ia) or (Ib) wherein the variables are as defined herein. In some aspects, the compounds may be used to inhibit the Wnt pathway and used to treat cancer, myocardial infarction, osteopetrosis, or used in the maturation of a precursor cell to a mature cell. Also provided herein in are pharmaceutical compositions of the compounds described herein.
-
公开(公告)号：US20180271848A1
公开(公告)日：2018-09-27
申请号：US15571240
申请日：2016-05-02
Inventor： Lawrence LUM , Chuo CHEN , Xuewu ZHANG , Ozlem KULAK , Xiaofeng WU
IPC: A61K31/454 , A61K45/06
Abstract: The present disclosure provides compounds that may be useful for inhibiting the Tankyrase enzyme. In some aspects, these compounds are useful in the treatment of a disease or disorder related to the misregulation of Tankyrase enzyme such as cancer, degenerative diseases, or fibrotic diseases. Also provided herein are compounds may also be used to prevent the elongation of the telomere in a cell.
-
公开(公告)号：US20150374696A1
公开(公告)日：2015-12-31
申请号：US14728105
申请日：2015-06-02
Inventor： Lawrence LUM , Michael G. ROTH , Baozhi CHEN , Chuo CHEN , Michael E. DODGE , Wei TANG
IPC: A61K31/519 , A61K31/502 , A61K45/06
CPC classification number: A61K31/519 , A61K31/502 , A61K45/06 , C07D209/48 , C07D209/94 , C07D239/54 , C07D401/10 , C07D401/12 , C07D401/14 , C07D403/10 , C07D413/04 , C07D417/12 , C07D471/04 , C07D519/00
Abstract: The present invention generally relates to protein signalling. In particular, compounds that inhibit the Wnt protein signalling pathway are disclosed. Such compounds may be used in the treatment of Wnt protein signalling-related diseases and conditions such as cancer, degenerative diseases, type II diabetes and osteopetrosis.
-
-
-
-
-
Search Results
6
records
(took 0.024 seconds)
